Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

RVNC ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 8, 2022 in the Class Action Filed on Behalf of Revance Therapeutics, Inc. Limited Shareholders

Newsfile January 16, 2022

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Revance Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022 - RVNC

Newsfile January 16, 2022

Revance Therapeutics Update

Newsfile January 16, 2022

Revance Therapeutics Inc. News: Berger Montague Investigates Securities Fraud Allegations Against Revance Therapeutics Inc. (RVNC); Lead Plaintiff Deadline is February 8, 2022

Newsfile January 15, 2022

Revance Therapeutics Class Action Reminder

Newsfile January 15, 2022

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Revance Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022 - RVNC

Newsfile January 14, 2022

Shareholder Action Notice: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile January 14, 2022

ROSEN, A LEADING LAW FIRM, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important February 8 Deadline in Securities Class Action - RVNC

Newsfile January 14, 2022

FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Revance Therapeutics, Inc. - RVNC

PR Newswire January 13, 2022

Revance Therapeutics Shareholder Notice

Newsfile January 13, 2022

Shareholder Action Alert: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile January 13, 2022

Revance Therapeutics Inc. News: Berger Montague Investigates Securities Fraud Allegations Against Revance Therapeutics Inc. (RVNC); Lead Plaintiff Deadline is February 8, 2022

Newsfile January 13, 2022

REVANCE THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNC

PR Newswire January 12, 2022

Revance Therapeutics Shareholder Alert

Newsfile January 12, 2022

Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Revance Therapeutics, Inc.

PR Newswire January 12, 2022

Investor Action Reminder: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile January 12, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - RVNC

Newsfile January 11, 2022

Lost Money in Revance Therapeutics, Inc.?

Business Wire January 11, 2022

Revance Therapeutics Deadline Alert

Newsfile January 11, 2022

Shareholder Action Notice: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile January 11, 2022